Shengyuan Zhang
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Polymerase-inhibitor drug synergy and mutational signatures in different epithelial cell models of RSVA and hPIV3 infection.
Journal: npj antimicrobials and resistance
Published: January 08, 2026
Nirmatrelvir-ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022-23: virological and immunological results of an open-label randomised trial (PANORAMIC).
Journal: The Lancet. Microbe
Published: March 25, 2025
Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2.
Journal: The Journal of clinical investigation
Published: February 07, 2025
Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2.
Journal: medRxiv : the preprint server for health sciences
Published: January 20, 2025
Efficient in vitro assay for evaluating drug efficacy and synergy against emerging SARS-CoV-2 strains.
Journal: Antimicrobial agents and chemotherapy
Published: December 17, 2024
A Viroimmunologic Model to Characterize the Antiviral Effect of Molnupiravir in Outpatients Infected With SARS-CoV-2: Implication for Treatment Duration.
Journal: The Journal of infectious diseases
Published: October 17, 2024
Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Studies Related to Vincristine-Induced Peripheral Neuropathy in Chinese Pediatric ALL Patients.
Journal: Clinical pharmacology and therapeutics
Published: July 29, 2024
SARS-CoV-2 viral dynamic modeling to inform model selection and timing and efficacy of antiviral therapy.
Journal: CPT: pharmacometrics & systems pharmacology
Published: April 14, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026